Direct effects of adipokines on the heart: Focus on adiponectin

Heart Failure Reviews

Volumn 18, Issue 5, 2013, Pages 631-644

  Park, Min ^a   Sweeney, Gary ^a  

^a YORK UNIVERSITY   (Canada)

Author keywords

Adipokines; Adiponectin; Cardiac remodeling; Cell death; Fibrosis; Heart failure; Hypertrophy; Metabolism; Obesity

Indexed keywords

ADENYLATE KINASE; ADIPOCYTOKINE; ADIPONECTIN; LIPOPROTEIN LIPASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

APOPTOSIS; AUTOPHAGY; BIOACCUMULATION; CELL SURVIVAL; CONFERENCE PAPER; DISEASE ACTIVITY; DISEASE ASSOCIATION; EXTRACELLULAR MATRIX; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; IN VIVO STUDY; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

ADIPOKINES; ADIPONECTIN; ANIMALS; CELL DEATH; HEART FAILURE; HUMANS; MYOCARDIUM; VENTRICULAR REMODELING;

EID: 84885329744     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-012-9337-8     Document Type: Conference Paper

References (147)

1. Gaddam KK, Ventura HO, Lavie CJ (2011) Metabolic syndrome and heart failure-the risk, paradox, and treatment. Curr Hypertens Rep 13(2):142-148. doi: 10.1007/s11906-011-0179-x
2. Mazzone T, Chait A, Plutzky J (2008) Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 371(9626):1800-1809. doi: 10.1016/S0140-6736(08)60768-0
3. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH (2006) Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 113(6):898-918. doi: 10.1161/CIRCULATIONAHA.106.171016
4. Anker SD, von Haehling S (2011) The obesity paradox in heart failure: accepting reality and making rational decisions. Clin Pharmacol Ther 90(1):188-190. doi: 10.1038/clpt.2011.72
5. Abel ED, Litwin SE, Sweeney G (2008) Cardiac remodeling in obesity. Physiol Rev 88(2):389-419
6. Boudina S, Abel ED (2010) Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 11(1):31-39. doi: 10.1007/s11154-010-9131-7
7. Smith CC, Yellon DM (2011) Adipocytokines, cardiovascular pathophysiology and myocardial protection. Pharmacol Ther 129(2):206-219. doi: 10.1016/j.pharmthera.2010.09.003
8. Walsh K (2009) Adipokines, myokines and cardiovascular disease. Circulation 73(1):13-18
9. Sattar N (2012) Biomarkers for diabetes prediction, pathogenesis or pharmacotherapy guidance? Past, present and future possibilities. Diabet Med J Br Diabet Assoc 29(1):5-13. doi: 10.1111/j.1464-5491.2011.03480.x
10. Yanavitski M, Givertz MM (2011) Novel biomarkers in acute heart failure. Curr Heart Fail Rep 8(3):206-211. doi: 10.1007/s11897-011-0065-5
11. Marette A, Sweeney G (2011) Recent insights in cardiovascular complications of diabetes. Expert Rev Endocrinol Metab 6(5):689-696
12. Abel ED, Sweeney G (2012) Modulation of the cardiovascular system by leptin. Biochimie. doi: 10.1016/j.biochi.2012.03.019
13. Sweeney G (2010) Cardiovascular effects of leptin. Nat Rev Cardiol 7(1):22-29. doi: 10.1038/nrcardio.2009.224
14. Tycinska AM, Lisowska A, Musial WJ, Sobkowicz B (2012) Apelin in acute myocardial infarction and heart failure induced by ischemia. Clin Chim Acta Int J Clin Chem 413(3-4):406-410. doi: 10.1016/j.cca.2011.11.021
15. Bhalla V, Kalogeropoulos A, Georgiopoulou V, Butler J (2010) Serum resistin: physiology, pathophysiology and implications for heart failure. Biomarkers Med 4(3):445-452. doi: 10.2217/bmm.10.17
16. Xu A, Vanhoutte PM (2012) Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease. Am J Physiol Heart Circ Physiol 302(6):H1231-H1240. doi: 10.1152/ajpheart.00765.2011
17. Fang X, Sweeney G (2006) Mechanisms regulating energy metabolism by adiponectin in obesity and diabetes. Biochem Soc Trans 34(Pt 5):798-801
18. Yamauchi T, Kadowaki T (2008) Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond) 32(Suppl 7):S13-S18. doi: 10.1038/ijo.2008.233
19. Waki H, Yamauchi T, Kamon J, Kita S, Ito Y, Hada Y, Uchida S, Tsuchida A, Takekawa S, Kadowaki T (2005) Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology 146(2):790-796
20. Wang Y, Lam KS, Chan L, Chan KW, Lam JB, Lam MC, Hoo RC, Mak WW, Cooper GJ, Xu A (2006) Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. J Biol Chem 281(24):16391-16400
21. Liu Y, Retnakaran R, Hanley A, Tungtrongchitr R, Shaw C, Sweeney G (2007) Total and high molecular weight but not trimeric or hexameric forms of adiponectin correlate with markers of the metabolic syndrome and liver injury in Thai subjects. J Clin Endocrinol Metab 92(11):4313-4318
22. Hui X, Lam KS, Vanhoutte PM, Xu A (2012) Adiponectin and cardiovascular health: an update. Br J Pharmacol 165(3):574-590. doi: 10.1111/j.1476-5381.2011. 01395.x
23. Shetty S, Kusminski CM, Scherer PE (2009) Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 30(5):234-239
24. Matsuzawa Y (2010) Adiponectin: a key player in obesity related disorders. Curr Pharm Des 16(17):1896-1901
25. Ouchi N, Shibata R, Walsh K (2006) Cardioprotection by adiponectin. Trends Cardiovasc Med 16(5):141-146
26. Ebert T, Fasshauer M (2011) Adiponectin: sometimes good, sometimes bad? Cardiology 118(4):236-237. doi: 10.1159/000329647
27. Fang X, Palanivel R, Cresser J, Schram K, Ganguly R, Thong FS, Tuinei J, Xu A, Abel ED, Sweeney G (2010) An APPL1-AMPK signaling axis mediates beneficial metabolic effects of adiponectin in the heart. Am J Physiol Endocrinol Metab 299(5):E721-E729. doi: 10.1152/ajpendo.00086.2010
28. Palanivel R, Fang X, Park M, Eguchi M, Pallan S, De Girolamo S, Liu Y, Wang Y, Xu A, Sweeney G (2007) Globular and full-length forms of adiponectin mediate specific changes in glucose and fatty acid uptake and metabolism in cardiomyocytes. Cardiovasc Res 75(1):148-157
29. Deepa SS, Dong LQ (2009) APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab 296(1):E22-E36. doi: 10.1152/ajpendo.90731.2008
30. Leroith D (2012) Pathophysiology of the metabolic syndrome: implications for the cardiometabolic risks associated with type 2 diabetes. Am J Med Sci 343(1):13-16. doi: 10.1097/MAJ.0b013e31823ea214
31. Despres JP, Cartier A, Cote M, Arsenault BJ (2008) The concept of cardiometabolic risk: bridging the fields of diabetology and cardiology. Ann Med 40(7):514-523. doi: 10.1080/07853890802004959
32. Ding G, Qin Q, He N, Francis-David SC, Hou J, Liu J, Ricks E, Yang Q (2007) Adiponectin and its receptors are expressed in adult ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator- activated receptor gamma. J Mol Cell Cardiol 43(1):73-84. doi: 10.1016/j.yjmcc.2007.04.014
33. Pineiro R, Iglesias MJ, Gallego R, Raghay K, Eiras S, Rubio J, Dieguez C, Gualillo O, Gonzalez-Juanatey JR, Lago F (2005) Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett 579(23):5163-5169. doi: 10.1016/j.febslet.2005.07.098
34. Lopaschuk GD (2008) AMP-activated protein kinase control of energy metabolism in the ischemic heart. Int J Obes (Lond) 32(Suppl 4):S29-S35. doi: 10.1038/ijo.2008.120
35. Onay-Besikci A, Altarejos JY, Lopaschuk GD (2004) gAd-globular head domain of adiponectin increases fatty acid oxidation in newborn rabbit hearts. J Biol Chem 279(43):44320-44326. doi: 10.1074/jbc.M400347200
36. Kim MS, Wang Y, Rodrigues B (2012) Lipoprotein lipase mediated fatty acid delivery and its impact in diabetic cardiomyopathy. Biochim Biophys Acta 1821(5):800-808. doi: 10.1016/j.bbalip.2011.10.001
37. Ganguly R, Schram K, Fang X, Kim M, Rodrigues B, Thong FS, Sweeney G (2011) Adiponectin increases LPL activity via RhoA/ROCK-mediated actin remodelling in adult rat cardiomyocytes. Endocrinology 152(1):247-254. doi: 10.1210/en.2010-0530
38. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, Gropler RJ (2004) Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 109(18):2191-2196. doi: 10.1161/01.CIR.0000127959.28627.F8
39. Liao Y, Takashima S, Maeda N, Ouchi N, Komamura K, Shimomura I, Hori M, Matsuzawa Y, Funahashi T, Kitakaze M (2005) Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 67(4):705-713
40. O'Shea KM, Chess DJ, Khairallah RJ, Rastogi S, Hecker PA, Sabbah HN, Walsh K, Stanley WC (2010) Effects of adiponectin deficiency on structural and metabolic remodeling in mice subjected to pressure overload. Am J Physiol Heart Circ Physiol 298(6):H1639-H1645. doi: 10.1152/ajpheart.00957.2009
41. Aerts JM, Ottenhoff R, Powlson AS, Grefhorst A, van Eijk M, Dubbelhuis PF, Aten J, Kuipers F, Serlie MJ, Wennekes T, Sethi JK, O'Rahilly S, Overkleeft HS (2007) Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 56(5):1341-1349
42. Holland WL, Brozinick JT, Wang LP, Hawkins ED, Sargent KM, Liu Y, Narra K, Hoehn KL, Knotts TA, Siesky A, Nelson DH, Karathanasis SK, Fontenot GK, Birnbaum MJ, Summers SA (2007) Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 5(3):167-179
43. Cheng KK, Lam KS, Wu D, Wang Y, Sweeney G, Hoo RL, Zhang J, Xu A (2012) APPL1 potentiates insulin secretion in pancreatic beta cells by enhancing protein kinase Akt-dependent expression of SNARE proteins in mice. Proc Natl Acad Sci USA 109(23):8919-24. doi: 10.1073/pnas.1202435109
44. Wang Y, Cheng KK, Lam KS, Wu D, Wang Y, Huang Y, Vanhoutte PM, Sweeney G, Li Y, Xu A (2011) APPL1 counteracts obesity-induced vascular insulin resistance and endothelial dysfunction by modulating the endothelial production of nitric oxide and endothelin-1 in mice. Diabetes 60(11):3044-3054. doi: 10.2337/db11-0666
45. Bernardo BC, Weeks KL, Pretorius L, McMullen JR (2010) Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther 128(1):191-227. doi: 10.1016/j.pharmthera.2010.04.005
46. Wang C, Li L, Zhang ZG, Fan D, Zhu Y, Wu LL (2010) Globular adiponectin inhibits angiotensin II-induced nuclear factor kappaB activation through AMP-activated protein kinase in cardiac hypertrophy. J Cell Physiol 222(1):149-155. doi: 10.1002/jcp.21931
47. Amin RH, Mathews ST, Alli A, Leff T (2010) Endogenously produced adiponectin protects cardiomyocytes from hypertrophy by a PPARgamma-dependent autocrine mechanism. Am J Physiol Heart Circ Physiol 299(3):H690-H698. doi: 10.1152/ajpheart.01032.2009
48. Essick EE, Ouchi N, Wilson RM, Ohashi K, Ghobrial J, Shibata R, Pimentel DR, Sam F (2011) Adiponectin mediates cardioprotection in oxidative stress-induced cardiac myocyte remodeling. Am J Physiol Heart Circ Physiol 301(3):H984-H993. doi: 10.1152/ajpheart.00428.2011
49. Shimano M, Ouchi N, Shibata R, Ohashi K, Pimentel DR, Murohara T, Walsh K (2010) Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response. J Mol Cell Cardiol 49(2):210-220. doi: 10.1016/j.yjmcc.2010.02.021
50. Shibata R, Izumiya Y, Sato K, Papanicolaou K, Kihara S, Colucci WS, Sam F, Ouchi N, Walsh K (2007) Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J Mol Cell Cardiol 42(6):1065-1074
51. Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, Kumada M, Sato K, Schiekofer S, Ohashi K, Funahashi T, Colucci WS, Walsh K (2004) Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10(12):1384-1389
52. Hecker PA, O'Shea KM, Galvao TF, Brown BH, Stanley WC (2011) Role of adiponectin in the development of high fat diet-induced metabolic abnormalities in mice. Horm Metab Res 43(2):100-105. doi: 10.1055/s-0030-1269898
53. Denzel MS, Scimia MC, Zumstein PM, Walsh K, Ruiz-Lozano P, Ranscht B (2010) T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 120(12):4342-4352. doi: 10.1172/JCI43464
54. Fujita K, Maeda N, Sonoda M, Ohashi K, Hibuse T, Nishizawa H, Nishida M, Hiuge A, Kurata A, Kihara S, Shimomura I, Funahashi T (2008) Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha. Arterioscler Thromb Vasc Biol 28(5):863-870
55. Kassiotis C, Ballal K, Wellnitz K, Vela D, Gong M, Salazar R, Frazier OH, Taegtmeyer H (2009) Markers of autophagy are downregulated in failing human heart after mechanical unloading. Circulation 120(11 Suppl):S191-S197. doi: 10.1161/CIRCULATIONAHA.108.842252
56. Chandrashekhar Y (2005) Role of apoptosis in ventricular remodeling. Curr Heart Fail Rep 2(1):18-22
57. Chiong M, Wang ZV, Pedrozo Z, Cao DJ, Troncoso R, Ibacache M, Criollo A, Nemchenko A, Hill JA, Lavandero S (2011) Cardiomyocyte death: mechanisms and translational implications. Cell Death Dis 2:e244. doi: 10.1038/cddis.2011.130
58. Baines CP (2011) How and when do myocytes die during ischemia and reperfusion: the late phase. J Cardiovasc Pharmacol Ther 16(3-4):239-243. doi: 10.1177/1074248411407769
59. Trivedi PS, Barouch LA (2008) Cardiomyocyte apoptosis in animal models of obesity. Curr Hypertens Rep 10(6):454-460
60. Yarbrough WM, Mukherjee R, Escobar GP, Sample JA, McLean JE, Dowdy KB, Hendrick JW, Gibson WC, Hardin AE, Mingoia JT, White PC, Stiko A, Armstrong RC, Crawford FA, Spinale FG (2003) Pharmacologic inhibition of intracellular caspases after myocardial infarction attenuates left ventricular remodeling: a potentially novel pathway. J Thorac Cardiovasc Surg 126(6):1892-1899
61. Neviere R, Hassoun SM, Decoster B, Bouazza Y, Montaigne D, Marechal X, Marciniak C, Marchetti P, Lancel S (2010) Caspase-dependent protein phosphatase 2A activation contributes to endotoxin-induced cardiomyocyte contractile dysfunction. Crit Care Med 38(10):2031-2036. doi: 10.1097/CCM.0b013e3181eedafb
62. Zitvogel L, Kepp O, Galluzzi L, Kroemer G (2012) Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 13(4):343-351. doi: 10.1038/ni.2224
63. Park M, Youn B, Zheng XL, Wu D, Xu A, Sweeney G (2011) Globular adiponectin, acting via AdipoR1/APPL1, protects H9c2 cells from hypoxia/reoxygenation-induced apoptosis. PLoS ONE 6(4):e19143. doi: 10.1371/journal.pone.0019143
64. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, Lopez BL, Koch W, Chan L, Goldstein BJ, Ma XL (2007) Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 115(11):1408-1416
65. Yi W, Sun Y, Gao E, Wei X, Lau WB, Zheng Q, Wang Y, Yuan Y, Wang X, Tao L, Li R, Koch W, Ma XL (2011) Reduced cardioprotective action of adiponectin in high-fat diet-induced type II diabetic mice and its underlying mechanisms. Antioxid Redox Signal 15(7):1779-1788. doi: 10.1089/ars.2010.3722
66. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, Davis KE, Bikman BT, Halberg N, Rutkowski JM, Wade MR, Tenorio VM, Kuo MS, Brozinick JT, Zhang BB, Birnbaum MJ, Summers SA, Scherer PE (2011) Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 17(1):55-63. doi: 10.1038/nm.2277
67. Konishi M, Haraguchi G, Ohigashi H, Ishihara T, Saito K, Nakano Y, Isobe M (2011) Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulation. Cardiovasc Res 89(2):309-319. doi: 10.1093/cvr/cvq335
68. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N, Walsh K (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11(10):1096-1103
69. Kondo K, Shibata R, Unno K, Shimano M, Ishii M, Kito T, Shintani S, Walsh K, Ouchi N, Murohara T (2010) Impact of a single intracoronary administration of adiponectin on myocardial ischemia/reperfusion injury in a pig model. Circ Cardiovasc Interv 3(2):166-173. doi: 10.1161/CIRCINTERVENTIONS.109.872044
70. Yang Z, Klionsky DJ (2010) Eaten alive: a history of macroautophagy. Nat Cell Biol 12(9):814-822. doi: 10.1038/ncb0910-814
71. Chen Y, Klionsky DJ (2011) The regulation of autophagy - unanswered questions. J Cell Sci 124(Pt 2):161-170. doi: 10.1242/jcs.064576
72. Dutta D, Calvani R, Bernabei R, Leeuwenburgh C, Marzetti E (2012) Contribution of impaired mitochondrial autophagy to cardiac aging: mechanisms and therapeutic opportunities. Circ Res 110(8):1125-1138. doi: 10.1161/CIRCRESAHA.111.246108
73. Xie M, Morales CR, Lavandero S, Hill JA (2011) Tuning flux: autophagy as a target of heart disease therapy. Curr Opin Cardiol 26(3):216-222. doi: 10.1097/HCO.0b013e328345980a
74. Mellor KM, Reichelt ME, Delbridge LM (2011) Autophagy anomalies in the diabetic myocardium. Autophagy 7(10):1263-1267. doi: 10.4161/auto.7.10.17148
75. Dong Y, Undyala VV, Gottlieb RA, Mentzer RM Jr, Przyklenk K (2010) Autophagy: definition, molecular machinery, and potential role in myocardial ischemia-reperfusion injury. J Cardiovasc Pharmacol Ther 15(3):220-230. doi: 10.1177/1074248410370327
76. Cao DJ, Gillette TG, Hill JA (2009) Cardiomyocyte autophagy: remodeling, repairing, and reconstructing the heart. Curr Hypertens Rep 11(6):406-411
77. Zhu H, Tannous P, Johnstone JL, Kong Y, Shelton JM, Richardson JA, Le V, Levine B, Rothermel BA, Hill JA (2007) Cardiac autophagy is a maladaptive response to hemodynamic stress. J Clin Invest 117(7):1782-1793. doi: 10.1172/JCI27523
78. Troncoso R, Vicencio JM, Parra V, Nemchenko A, Kawashima Y, Del Campo A, Toro B, Battiprolu PK, Aranguiz P, Chiong M, Yakar S, Gillette TG, Hill JA, Abel ED, Leroith D, Lavandero S (2012) Energy-preserving effects of IGF-1 antagonize starvation-induced cardiac autophagy. Cardiovasc Res 93(2):320-329. doi: 10.1093/cvr/cvr321
79. Sugimoto S, Shiomi K, Yamamoto A, Nishino I, Nonaka I, Ohi T (2007) LAMP-2 positive vacuolar myopathy with dilated cardiomyopathy. Intern Med 46(11):757-760
80. Mihaylova MM, Shaw RJ (2011) The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 13(9):1016-1023. doi: 10.1038/ncb2329
81. Habeeb BS, Kitayama J, Nagawa H (2011) Adiponectin supports cell survival in glucose deprivation through enhancement of autophagic response in colorectal cancer cells. Cancer Sci 102(5):999-1006. doi: 10.1111/j.1349-7006.2011.01902.x
82. He C, Bassik MC, Moresi V, Sun K, Wei Y, Zou Z, An Z, Loh J, Fisher J, Sun Q, Korsmeyer S, Packer M, May HI, Hill JA, Virgin HW, Gilpin C, Xiao G, Bassel-Duby R, Scherer PE, Levine B (2012) Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature 481(7382):511-515. doi: 10.1038/nature10758
83. Aviv Y, Shaw J, Gang H, Kirshenbaum LA (2011) Regulation of autophagy in the heart: "you only live twice". Antioxid Redox Signal 14(11):2245-2250. doi: 10.1089/ars.2010.3479
84. Gurusamy N, Das DK (2009) Is autophagy a double-edged sword for the heart? Acta Physiol Hung 96(3):267-276. doi: 10.1556/APhysiol.96.2009.3.2
85. Fomovsky GM, Thomopoulos S, Holmes JW (2010) Contribution of extracellular matrix to the mechanical properties of the heart. J Mol Cell Cardiol 48(3):490-496. doi: 10.1016/j.yjmcc.2009.08.003
86. Hutchinson KR, Stewart JA Jr, Lucchesi PA (2010) Extracellular matrix remodeling during the progression of volume overload-induced heart failure. J Mol Cell Cardiol 48(3):564-569. doi: 10.1016/j.yjmcc.2009.06.001
87. Schram K, Sweeney G (2008) Implications of myocardial matrix remodeling by adipokines in obesity-related heart failure. Trends Cardiovasc Med 18(6):199-205. doi: 10.1016/j.tcm.2008.10.001
88. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291(14):1730-1737
89. Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zethelius B (2007) Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 92(2):571-576
90. Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H (2006) Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol 48(7):1369-1377
91. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB (2005) Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 54(2):534-539
92. Laughlin GA, Barrett-Connor E, May S, Langenberg C (2007) Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol 165(2):164-174
93. Kawano T, Saito T, Yasu T, Nakamura T, Namai K, Tamemoto H, Kawakami M, Saito M, Ishikawa SE (2005) Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. Metabolism 54(5):653-656
94. Hong SJ, Park CG, Seo HS, Oh DJ, Ro YM (2004) Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press 13(4):236-242
95. Chen WJ, Rijzewijk LJ, van der Meer RW, Heymans MW, van Duinkerken E, Lubberink M, Lammertsma AA, Lamb HJ, de Roos A, Romijn JA, Smit JW, Bax JJ, Bjerre M, Frystyk J, Flyvbjerg A, Diamant M (2011) Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men. Cardiovasc Diabetol 10:67. doi: 10.1186/1475-2840-10-67
96. Bidulescu A, Liu J, Musani SK, Fox ER, Samdarshi TE, Sarpong DF, Vaccarino V, Wilson PW, Arnett DK, Din-Dzietham R, Taylor HA, Gibbons GH (2011) Association of adiponectin with left ventricular mass in blacks: the Jackson Heart Study. Circ Heart Fail 4(6):747-753. doi: 10.1161/CIRCHEARTFAILURE.110. 959742
97. Unno K, Shibata R, Izawa H, Hirashiki A, Murase Y, Yamada T, Kobayashi M, Noda A, Nagata K, Ouchi N, Murohara T (2010) Adiponectin acts as a positive indicator of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy. Heart 96(5):357-361. doi: 10.1136/hrt.2009.172320
98. Kanaya AM, Wassel Fyr C, Vittinghoff E, Havel PJ, Cesari M, Nicklas B, Harris T, Newman AB, Satterfield S, Cummings SR (2006) Serum adiponectin and coronary heart disease risk in older Black and White Americans. J Clin Endocrinol Metab 91(12):5044-5050
99. George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y, Grossman E, Sheps D, Keren G, Roth A (2006) Circulating adiponectin concentrations in patients with congestive heart failure. Heart 92(10):1420-1424
100. Cavusoglu E, Chopra V, Battala V, Ruwende C, Yanamadala S, Eng C, Pinsky DJ, Marmur JD (2008) Baseline plasma adiponectin levels as a predictor of left ventricular systolic dysfunction in patients referred for coronary angiography. Am J Cardiol 101(8):1073-1078. doi: 10.1016/j.amjcard.2007.12.008
101. McEntegart MB, Awede B, Petrie MC, Sattar N, Dunn FG, MacFarlane NG, McMurray JJ (2007) Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 28(7):829-835. doi: 10.1093/eurheartj/ ehm033
102. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P (2005) Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112(12):1756-1762. doi: 10.1161/CIRCULATIONAHA.104.530972
103. Nakamura T, Funayama H, Kubo N, Yasu T, Kawakami M, Saito M, Momomura S, Ishikawa SE (2006) Association of hyperadiponectinemia with severity of ventricular dysfunction in congestive heart failure. Circulation 70(12):1557-1562
104. Beatty AL, Zhang MH, Ku IA, Na B, Schiller NB, Whooley MA (2012) Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: Data from the Heart and Soul Study. Atherosclerosis 220(2):587-92. doi: 10.1016/j.atherosclerosis.2011.11.038
105. Kozakova M, Muscelli E, Flyvbjerg A, Frystyk J, Morizzo C, Palombo C, Ferrannini E (2008) Adiponectin and left ventricular structure and function in healthy adults. J Clin Endocrinol Metab 93(7):2811-2818. doi: 10.1210/jc.2007-2580
106. Gustafsson S, Lind L, Zethelius B, Venge P, Flyvbjerg A, Soderberg S, Ingelsson E (2010) Adiponectin and cardiac geometry and function in elderly: results from two community-based cohort studies. Eur J Endocrinol 162(3):543-550. doi: 10.1530/EJE-09-1006
107. Xu A, Chan KW, Hoo RL, Wang Y, Tan KC, Zhang J, Chen B, Lam MC, Tse C, Cooper GJ, Lam KS (2005) Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 280(18):18073-18080. doi: 10.1074/jbc.M414231200
108. Arai Y, Takayama M, Abe Y, Hirose N (2011) Adipokines and aging. J Atheroscler Thromb 18(7):545-550
109. Kadowaki T, Yamauchi T, Kubota N (2008) The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Lett 582(1):74-80. doi: 10.1016/j.febslet.2007. 11.070
110. Dadson K, Liu Y, Sweeney G (2011) Adiponectin action: a combination of endocrine and autocrine/paracrine effects. Front Cell Endocrinol 2(62):1-14
111. Palanivel R, Vu V, Park M, Fang X, Sweeney G (2008) Differential impact of adipokines derived from primary adipocytes of wild-type versus streptozotocin-induced diabetic rats on glucose and fatty acid metabolism in cardiomyocytes. J Endocrinol 199(3):389-397. doi: 10.1677/JOE-08-0336
112. Fang X, Fetros J, Dadson KE, Xu A, Sweeney G (2009) Leptin prevents the metabolic effects of adiponectin in L6 myotubes. Diabetologia 52(10):2190-2200. doi: 10.1007/s00125-009-1462-0
113. Yoon JH, Park JK, Oh SS, Lee KH, Kim SK, Cho IJ, Kim JK, Kang HT, Ahn SG, Lee JW, Lee SH, Eom A, Kim JY, Ahn SV, Koh SB (2011) The ratio of serum leptin to adiponectin provides adjunctive information to the risk of metabolic syndrome beyond the homeostasis model assessment insulin resistance: the Korean Genomic Rural Cohort Study. Clin Chim Acta Int J Clin Chem 412(23-24):2199-2205. doi: 10.1016/j.cca.2011.08.003
114. Ebinuma H, Miida T, Yamauchi T, Hada Y, Hara K, Kubota N, Kadowaki T (2007) Improved ELISA for selective measurement of adiponectin multimers and identification of adiponectin in human cerebrospinal fluid. Clin Chem 53(8):1541-1544. doi: 10.1373/clinchem.2007.085654
115. Lopez L (2009) Advances in echocardiography. Curr Opin Pediatr 21(5):579-584. doi: 10.1097/MOP.0b013e32832ff38e
116. Ohara T, Hashimura K, Asakura M, Ogai A, Amaki M, Hasegawa T, Kanzaki H, Sonoda M, Nishizawa H, Funahashi T, Kitakaze M (2011) Dynamic changes in plasma total and high molecular weight adiponectin levels in acute heart failure. J Cardiol 58(2):181-190. doi: 10.1016/j.jjcc.2011.06.010
117. Masson S, Gori F, Latini R, Milani V, Flyvbjerg A, Frystyk J, Crociati L, Pietri S, Vago T, Barlera S, Maggioni AP, Tognoni G, Tavazzi L, Omland T, Franzosi MG (2011) Adiponectin in chronic heart failure: influence of diabetes and genetic variants. Eur J Clin Invest 41(12):1330-1338. doi: 10.1111/j.1365-2362.2011.02548.x
118. Pedersen BK, Febbraio MA (2008) Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Phys Rev 88(4):1379-1406. doi: 10.1152/physrev.90100.2007
119. Skurk C, Wittchen F, Suckau L, Witt H, Noutsias M, Fechner H, Schultheiss HP, Poller W (2008) Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy. Eur Heart J 29(9):1168-1180. doi: 10.1093/eurheartj/ehn136
120. Liao Y, Xuan W, Zhao J, Bin J, Zhao H, Asakura M, Funahashi T, Takashima S, Kitakaze M (2010) Antihypertrophic effects of adiponectin on cardiomyocytes are associated with the inhibition of heparin-binding epidermal growth factor signaling. Biochem Biophys Res Commun 393(3):519-525. doi: 10.1016/j.bbrc.2010. 02.039
121. Haugen E, Furukawa Y, Isic A, Fu M (2008) Increased adiponectin level in parallel with increased NT-pro BNP in patients with severe heart failure in the elderly: a hospital cohort study. Int J Cardiol 125(2):216-219. doi: 10.1016/j.ijcard.2007.12.002
122. Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A, Okazaki H, Asai M, Nagamachi Y, Maeda N, Shintani Y, Minamino T, Asakura M, Kishimoto I, Funahashi T, Tomoike H, Kitakaze M (2009) Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 53(22):2070-2077. doi: 10.1016/j.jacc.2009.02.038
123. Kintscher U (2007) Does adiponectin resistance exist in chronic heart failure? Eur Heart J 28(14):1676-1677. doi: 10.1093/eurheartj/ehm233
124. Khan RS, Kato TS, Chokshi A, Chew M, Yu S, Wu C, Singh P, Cheema FH, Takayama H, Harris C, Reyes-Soffer G, Knoll R, Milting H, Naka Y, Mancini D, Schulze PC (2012) Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: correction after ventricular assist device implantation. Circ Heart Fail 5(3):340-348. doi: 10.1161/CIRCHEARTFAILURE.111. 964031
125. Li R, Lau WB, Ma XL (2010) Adiponectin resistance and vascular dysfunction in the hyperlipidemic state. Acta Pharmacol Sin 31(10):1258-1266. doi: 10.1038/aps.2010.95
126. Van Berendoncks AM, Garnier A, Beckers P, Hoymans VY, Possemiers N, Fortin D, Van Hoof V, Dewilde S, Vrints CJ, Ventura-Clapier R, Conraads VM (2011) Exercise training reverses adiponectin resistance in skeletal muscle of patients with chronic heart failure. Heart 97(17):1403-1409. doi: 10.1136/hrt.2011.226373
127. Springer J, Anker SD, Doehner W (2010) Adiponectin resistance in heart failure and the emerging pattern of metabolic failure in chronic heart failure. Circ Heart Fail 3(2):181-182. doi: 10.1161/CIRCHEARTFAILURE.110.945063
128. Van Berendoncks AM, Garnier A, Beckers P, Hoymans VY, Possemiers N, Fortin D, Martinet W, Van Hoof V, Vrints CJ, Ventura-Clapier R, Conraads VM (2010) Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure. Circ Heart Fail 3(2):185-194. doi: 10.1161/CIRCHEARTFAILURE.109.885525
129. Lin HV, Kim JY, Pocai A, Rossetti L, Shapiro L, Scherer PE, Accili D (2007) Adiponectin resistance exacerbates insulin resistance in insulin receptor transgenic/knockout mice. Diabetes 56(8):1969-1976. doi: 10.2337/db07-0127
130. Mullen KL, Smith AC, Junkin KA, Dyck DJ (2007) Globular adiponectin resistance develops independently of impaired insulin-stimulated glucose transport in soleus muscle from high-fat-fed rats. Am J Physiol Endocrinol Metab 293(1):E83-E90. doi: 10.1152/ajpendo.00545.2006
131. Fang X, Palanivel R, Zhou X, Liu Y, Xu A, Wang Y, Sweeney G (2005) Hyperglycemia- and hyperinsulinemia-induced alteration of adiponectin receptor expression and adiponectin effects in L6 myoblasts. J Mol Endocrinol 35(3):465-476. doi: 10.1677/jme.1.01877
132. Van Berendoncks AM, Conraads VM (2011) Functional adiponectin resistance and exercise intolerance in heart failure. Curr Heart Fail Rep 8(2):113-122. doi: 10.1007/s11897-011-0056-6
133. Wang T, Qiao S, Lei S, Liu Y, Ng KF, Xu A, Lam KS, Irwin MG, Xia Z (2011) N-acetylcysteine and allopurinol synergistically enhance cardiac adiponectin content and reduce myocardial reperfusion injury in diabetic rats. PLoS ONE 6(8):e23967. doi: 10.1371/journal.pone.0023967
134. Jang Y, Lee JH, Wang Y, Sweeney G (2012) Emerging clinical and experimental evidence for the role of lipocalin-2 in metabolic syndrome. Clin Exp Pharmacol Physiol 39(2):194-199. doi: 10.1111/j.1440-1681.2011.05557.x
135. Wang Y, Lam KS, Kraegen EW, Sweeney G, Zhang J, Tso AW, Chow WS, Wat NM, Xu JY, Hoo RL, Xu A (2007) Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 53(1):34-41. doi: 10.1373/clinchem.2006.075614
136. Law IK, Xu A, Lam KS, Berger T, Mak TW, Vanhoutte PM, Liu JT, Sweeney G, Zhou M, Yang B, Wang Y (2010) Lipocalin-2 deficiency attenuates insulin resistance associated with aging and obesity. Diabetes 59(4):872-882. doi: 10.2337/db09-1541
137. Latouche C, El Moghrabi S, Messaoudi S, Nguyen Dinh Cat A, Hernandez-Diaz I, Alvarez de la Rosa D, Perret C, Lopez Andres N, Rossignol P, Zannad F, Farman N, Jaisser F (2012) Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system. Hypertension 59(5):966-972. doi: 10.1161/HYPERTENSIONAHA.111.187872
138. Ding L, Hanawa H, Ota Y, Hasegawa G, Hao K, Asami F, Watanabe R, Yoshida T, Toba K, Yoshida K, Ogura M, Kodama M, Aizawa Y (2010) Lipocalin-2/neutrophil gelatinase-B associated lipocalin is strongly induced in hearts of rats with autoimmune myocarditis and in human myocarditis. Circulation 74(3):523-530
139. Choi KM, Lee JS, Kim EJ, Baik SH, Seo HS, Choi DS, Oh DJ, Park CG (2008) Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J Endocrinol 158(2):203-207. doi: 10.1530/EJE-07-0633
140. Aigner F, Maier HT, Schwelberger HG, Wallnofer EA, Amberger A, Obrist P, Berger T, Mak TW, Maglione M, Margreiter R, Schneeberger S, Troppmair J (2007) Lipocalin-2 regulates the inflammatory response during ischemia and reperfusion of the transplanted heart. Am J Transplant 7(4):779-788. doi: 10.1111/j.1600-6143.2006.01723.x
141. Yang B, Fan P, Xu A, Lam KS, Berger T, Mak TW, Tse HF, Yue JW, Song E, Vanhoutte PM, Sweeney G, Wang Y (2012) Improved functional recovery to I/R injury in hearts from lipocalin-2 deficiency mice: restoration of mitochondrial function and phospholipids remodeling. Am J Transl Res 4(1):60-71
142. Xu G, Ahn J, Chang S, Eguchi M, Ogier A, Han S, Park Y, Shim C, Jang Y, Yang B, Xu A, Wang Y, Sweeney G (2012) Lipocalin-2 induces cardiomyocyte apoptosis by increasing intracellular iron accumulation. J Biol Chem 287(7):4808-4817. doi: 10.1074/jbc.M111.275719
143. Murphy CJ, Oudit GY (2010) Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J Card Fail 16(11):888-900. doi: 10.1016/j.cardfail. 2010.05.009
144. Gujja P, Rosing DR, Tripodi DJ, Shizukuda Y (2010) Iron overload cardiomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol 56(13):1001-1012. doi: 10.1016/j.jacc.2010.03.083
145. Sommer P, Sweeney G (2010) Functional and mechanistic integration of infection and the metabolic syndrome. Korean Diabetes J 34(2):71-76. doi: 10.4093/kdj.2010.34.2.71
146. Yndestad A, Landro L, Ueland T, Dahl CP, Flo TH, Vinge LE, Espevik T, Froland SS, Husberg C, Christensen G, Dickstein K, Kjekshus J, Oie E, Gullestad L, Aukrust P (2009) Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J 30(10):1229-1236. doi: 10.1093/eurheartj/ehp088
147. Mann DL (2011) The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res 108(9):1133-1145. doi: 10.1161/CIRCRESAHA.110.226936